Dyslipidemia | Landscape & Forecast | Disease Landscape & Forecast

Publish date: July 2019

Login to access report


Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9 inhibitors, focus on improving lipid levels with an end goal to achieve CV risk reduction. Statins dominate the market owing to their good risk-benefit profile and evidence for reducing CV morbidity and mortality. The positive CV outcomes data for certain nonstatin therapies such as PCSK9 inhibitors and Vascepa are expected to influence the market penetration of these branded agents. The launches of emerging therapies, including The Medicines Company/Alnylam Pharmaceuticals’ inclisiran, Esperion Therapeutics’ bempedoic acid, and AstraZeneca’s Epanova, during the forecast period are anticipated to further enhance the dyslipidemia market.


  • What is the impact of genericization of statins, and Merck’s Zetia/Ezetrol (ezetimibe) and Vytorin/Inegy (ezetimibe/simvastatin) on the dyslipidemia market?
  • How are the PCSK9 inhibitors positioned in the dyslipidemia market? How have positive CV outcomes data and price reductions influenced the market penetration of Repatha (evolocumab) and Praluent (alirocumab)?
  • How will the anticipated launch of Esperion Therapeutics’ orally administered bempedoic acid affect the use of the injectable PCSK9 inhibitors? Which products will achieve the greatest use and why?
  • What impact will the anticipated launch of AstraZeneca’s Epanova have on the management of hypertriglyceridemia?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 20 country-specific interviews with thought-leading lipidologists Supported by survey data collected for this and other DRG research

Epidemiology: Prevalent cases of dyslipidemia by country, cardiovascular disease prevention setting, and diagnosed/drug-treated populations

Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.

Market forecast features: 10-year, annualized, drug-level sales and patient share of key dyslipidemia therapies through 2028, segmented by brands/generics and cardiovascular disease prevention setting.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • July 2019
      • June 2019
      • November 2018
      • September 2018
      • August 2018
      • June 2018
      • October 2017
    • Executive Summary
      • Key Findings
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Dyslipidemia?
        • What Factors Are Constraining the Market for Dyslipidemia?
      • Drug-Class-Specific Trends
        • Statins
        • Cholesterol Absorption Inhibitors
        • PCSK9 Inhibitors
        • ACL Inhibitors
        • PPAR Modulators
        • Omega-3 Fatty Acid Compounds
        • BET Inhibitors
        • Bile Acid Sequestrants (Resins)
        • Niacin Derivatives
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Etiology
      • Pathophysiology
      • Natural History
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
        • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases of Primary and Secondary Prevention Dyslipidemia
        • Diagnosed Prevalent Cases of Dyslipidemia
        • Drug-Treated Cases of Dyslipidemia
    • Current Treatment
      • Key Findings
        • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Statins
        • Cholesterol Absorption Inhibitors
        • Bile Acid Sequestrants
        • PCSK9 Inhibitors
        • PPAR Modulators
        • Omega-3 Fatty Acid Compounds
        • Niacin Derivatives
        • Treatments for Rare Lipid Disorders
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Country-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Dyslipidemia
    • Emerging Therapies
      • Key Findings
        • Expert Insight
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Dyslipidemia
        • PCSK9 Inhibitors
        • Omega-3 Fatty Acid Compounds
        • CETP Inhibitors
        • ACL Inhibitors
        • BET Inhibitors
        • Apolipoprotein-CIII Antagonists
        • Fixed-Dose Combinations
        • Angiopoietin-like Protein 3 (ANGPTL3) Inhibitor
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in Dyslipidemia
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Dyslipidemia Bibliography

Author(s): Pallavi Malik, M.Sc

Pallavi Malik is a business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Biotechnology, and a Bachelor's degree in Science from the Panjab University, Chandigarh, India. Prior to joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve. Her role involved in-depth scientific secondary research, and competitive intelligence across multiple domains (such as oncology, ophthalmology and CVD) including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, competitor benchmarking, and opportunity assessment.